公开(公告)号：US11229643B2

公开(公告)日：2022-01-25

申请号：US16347194

申请日：2017-11-01

Applicant: NOVARTIS AG

Inventor： Robin Alec Fairhurst ,  Diana Graus Porta ,  Jacqueline Kinyamu-Akunda ,  Andreas Joerg Mahl ,  Luigi Manenti ,  Andreas Weiss ,  Armin Wolf ,  Kuno Wuersch

IPC: A61K31/496 ,  A61K31/14

Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.

公开(公告)号：US20240245670A1

公开(公告)日：2024-07-25

申请号：US17415923

申请日：2019-12-19

Applicant: Novartis AG

Inventor： Simone BONAZZI ,  Adam Crystal ,  John Scott Cameron ,  Eva Marie Genevieve D'Hennezel ,  Glenn Dranoff ,  Ry Roger Forseth ,  Dominik Johannes Hainzl ,  Jacqueline Kinyamu-Akunda ,  Guiqing Liang ,  Lilly Mary Petruzzelli

IPC: A61K31/4545 ,  A61K9/00 ,  A61K31/55 ,  A61P35/00

CPC classification number: A61K31/4545 ,  A61K9/0053 ,  A61K31/55 ,  A61P35/00

Abstract: The present disclosure relates to dosing regimens, formulations, and combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds or pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases or disorders or where reduction of IKZF2 or IKZF4 protein levels can ameliorate a disease, for example, the treatment of cancers.